Skip to main content

Combo therapy slows prostate cancer

Oct. 19, 2021, 8:00 AM

by Leigh MacMillan

Despite the success of anti-androgen treatment for metastatic prostate cancer, nearly all patients will eventually progress to castration-resistant prostate cancer (CRPC). 

Ren Jie Jin, PhD, and colleagues previously found that long-term anti-androgen treatment increases the expression of the neuroendocrine hormone, GRP, and its receptor, GRP-R, in prostate cancer cells. They showed that GRP/GRP-R signaling promotes the expression of androgen receptor splice variants (which are active in the presence of anti-androgen drugs) and cancer progression to CRPC. 

In studies reported in Translational Oncology, they now demonstrate that blocking GRP-R signaling with a selective antagonist efficiently inhibits the expression of androgen receptor splice variants and sensitizes CRPC cells to anti-androgen treatment. In animal models, combining the GRP-R antagonist with anti-androgen treatment slowed the growth of both CRPC and therapy-induced neuroendocrine prostate cancer. 

The findings support the potential of this combination therapy as a new approach for treating CRPC.

This research was supported by the Ferring Innovation Grant from the Ferring Research Institute and by the W. L. Bray Endowment.

Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
VUMC Voice